Like CTLA-4, TIGIT also has its positive counterpart CD226, which promotes cytotoxicity and enhances anti-tumor responses, executing immunostimulatory functions when binds to CD155 and CD112, however, TIGIT has much higher affinity than CD226 (57). Here, TIGIT is linked to neoplasm.